I’ve been very critical of PR having the multiple roles (not Robinson Crusoe) but when you are CEO OR MD there’s no excuse for taking on multiple roles so hat’s off for finally reading the room (tad late in any event). Things could come together - good MPS results soon, positive FDA discussions and outcome for the 2 mg dose, then a potential deal for MPS or OA in China, SP appreciation leading to options being in the money and another 35 odd million although some more dilution. 2025 could then be better with TGA approval and submission of NDA.GLTA
General OA media and info, page-430
-
- There are more pages in this discussion • 241 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 25.0¢ | 23.0¢ | $101.6K | 424.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 144266 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 18540 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |